Medications for Esophageal Neoplasms
6 results
Capecitabine (capecitabine)
(capecitabine)BluePoint Laboratories
Usage: Capecitabine is indicated for the treatment of various cancers, including Stage III colon cancer, locally advanced rectal cancer, unresectable or metastatic colorectal cancer, advanced or metastatic breast cancer, and unresectable or metastatic gastric and pancreatic cancers, often in combination with other chemotherapy agents.
Capecitabine (capecitabine)
(Capecitabine)Aurobindo Pharma Limited
Usage: Capecitabine tablets are indicated for the treatment of Stage III colon cancer, locally advanced rectal cancer, unresectable or metastatic colorectal cancer, advanced or metastatic breast cancer, unresectable gastric or esophageal cancers, and as adjuvant therapy for pancreatic adenocarcinoma in combination with chemotherapy regimens.
E-z-hd (barium sulfate)
(barium sulfate)E-Z-EM Canada Inc
Usage: E-Z-HD is indicated for double-contrast radiographic examinations of the esophagus, stomach, and duodenum, aiding visualization of the gastrointestinal tract in patients aged 12 and older.
Keytruda (pembrolizumab)
(pembrolizumab)Merck Sharp & Dohme LLC
Usage: KEYTRUDA® is indicated for treating various cancers, including melanoma, non-small cell lung cancer, malignant pleural mesothelioma, head and neck squamous cell cancer, classical Hodgkin lymphoma, and possible others, in both adults and children, depending on specific tumor characteristics and treatment history.
Opdivo (nivolumab)
(nivolumab)E.R. Squibb & Sons, L.L.C.
Usage: OPDIVO is indicated for the treatment of various cancers, including unresectable or metastatic melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, advanced renal cell carcinoma (RCC), classical Hodgkin lymphoma, and more, in both adults and pediatric patients. It can be used alone or in combination therapies.
Yervoy (ipilimumab)
(ipilimumab)E.R. Squibb & Sons, L.L.C.
Usage: YERVOY is indicated for treating unresectable or metastatic melanoma, adjuvant treatment for resected melanoma, advanced renal cell carcinoma, microsatellite instability-high or mismatch repair deficient colorectal cancer, unresectable hepatocellular carcinoma, metastatic non-small cell lung cancer, malignant pleural mesothelioma, and unresectable esophageal squamous cell carcinoma.